IRVINE, Calif.–(BUSINESS WIRE)–#ClinicalTrials—Immunis, Inc., a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead, will present at the exclusive 13D Brain Trust Conference in the Bahamas. Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities. Like its name, the Brain Trust Conference invites the world’s greatest minds to realize their visions for the world.
Dr. Hans Keirstead, a venerated scientist with an impressive track record of founding multiple, successful biotech companies, will engage the audience on the transformative scientific innovation that is hoping to extend human healthspan. It has become increasingly evident that immune system dysfunction is at the heart of all age-related diseases. Thus, immunomodulation is an attractive approach for improving human health. Enter, Immunis.
Immunis’ cutting-edge immunomodulatory secretome is aimed at combating age and immune-related diseases. The company’s leading product, IMMUNA, has shown promising pre-clinical results in enhancing muscle regeneration, muscle function, and metabolism. Dr. Keirstead will feature IMMUNA’s journey from scientific production to first-in-human clinical trials, underscoring its significant potential in reversing age-related muscle atrophy.
We thank the Brain Trust Conference for honoring Dr. Keirstead as a guest speaker and for including Immunis in the atmosphere of intellectual exchange to propel humanity forward.
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
Contacts